home / stock / snynf / snynf news


SNYNF News and Press, Sanofi From 05/10/24

Stock Information

Company Name: Sanofi
Stock Symbol: SNYNF
Market: OTC
Website: sanofi.com

Menu

SNYNF SNYNF Quote SNYNF Short SNYNF News SNYNF Articles SNYNF Message Board
Get SNYNF Alerts

News, Short Squeeze, Breakout and More Instantly...

SNYNF - Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines

Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines Agreement provides patients with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strengt...

SNYNF - International Wide-Moat Stocks On Sale - The May 2024 Heat Map

2024-05-08 12:01:57 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investible candidates that may b...

SNYNF - Regeneron falls after Q1 miss; announces $3B share buybacks

2024-05-02 07:55:40 ET More on Regeneron Pharmaceuticals Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript) Regeneron Pharmaceuticals, Inc. (REGN) Barclays ...

SNYNF - Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations

Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus n...

SNYNF - Sanofi Q1: Wait And See For Now (Downgrade)

2024-05-01 14:27:40 ET Summary Sanofi acquired Inbrx to add lung disorders to its treatment portfolio, with an estimated sales peak of €600 million by 2032. The company settled 4,000 lawsuits related to Zantac, which is not expected to impact its balance sheet significantly...

SNYNF - Press Release: Annual General Meeting of April 30, 2024

Annual General Meeting of April 30, 2024 Approval of the financial statements for the fiscal year 2023 Distribution of a cash dividend of €3.76 per share, with payment as of May 15, 2024 Board composition: renewal of two Directors and appointment of three new Independent Di...

SNYNF - Sanofi: Q1 Earnings Reflect Growth And Strategic Acquisitions (Rating Upgrade)

2024-04-30 11:30:18 ET Summary Sanofi beat Q1 earnings estimates with revenue at $11.36 billion and EPS at 97 cents, driven largely by Dupixent. Key drugs like Nexviazyme and Altuviiio showed strong performance, with the former doubling its revenue. Despite a high profitabilit...

SNYNF - These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)

2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...

SNYNF - Sanofi (SNY) Q1 2024 Earnings Call Transcript

2024-04-25 11:24:10 ET Sanofi (SNY) Q1 2024 Earnings Conference Call April 25, 2024 08:30 AM ET Company Participants Paul Hudson - Chief Executive Officer François-Xavier Roger - Chief Financial Officer Houman Ashrafian - Executive Vice President & Head-...

SNYNF - Sanofi Non-GAAP EPS of Euro1.78, revenue of Euro10.46B; reaffirms FY24 business EPS guidance

2024-04-25 01:38:35 ET More on Sanofi: Sanofi: My Top Pick In Big Pharma Sanofi reportedly lining up banks for consumer products spinoff Sanofi succeeds in late-stage trial for blood disorder candidate Read the full article on Seeking Alpha For furthe...

Previous 10 Next 10